Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma

NCT02633137 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

49

Enrollment

OTHER

Sponsor class

Conditions

Mantle Cell Lymphoma
Untreated

Interventions

DRUG: Lenalidomide
DRUG: R-CHOP
DRUG: high-dose cytarabine (HIDAC)

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]